Efficacy of oral fluoroquinolones versus conventional intravenous antipseudomonal chemotherapy in treatment of cystic fibrosis

European Journal of Clinical Microbiology

Volumn 6, Issue 6, 1987, Pages 618-622

  Jensen, T ^a   Pedersen, S S ^a   HoSiby N ^a   Koch, C ^a  

^a Rigshospitalet   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; AZTREONAM; CEFSULODIN; CEFTAZIDIME; CILASTATIN; CIPROFLOXACIN; IMIPENEM; OFLOXACIN; PIPERACILLIN; PRECIPITIN; TOBRAMYCIN;

CLINICAL ARTICLE; CYSTIC FIBROSIS; DRUG EFFICACY; HUMAN; LUNG FUNCTION TEST; PSEUDOMONAS AERUGINOSA;

ADULT; ANTI-INFECTIVE AGENTS; CHRONIC DISEASE; CIPROFLOXACIN; CLINICAL TRIALS; COMPARATIVE STUDY; CYSTIC FIBROSIS; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; MALE; OFLOXACIN; OXAZINES; PEAK EXPIRATORY FLOW RATE; PROSPECTIVE STUDIES; PSEUDOMONAS INFECTIONS; RANDOM ALLOCATION; VITAL CAPACITY;

EID: 0023470681     PISSN: 07222211     EISSN: 14354373     Source Type: Journal    
DOI: 10.1007/BF02013055     Document Type: Article

References (20)

1. Does centralized treatment of cystic fibrosis increase the risk of Pseudomonas aeruginosa infection?
2. Pseudomonas aeruginosa infection in cystic fibrosis. Diagnostic and prognostic significance of Pseudomonas aeruginosa precipitins determined by means of crossed immunoelectrophoresis
3. Antimicrobial chemotherapy in cystic fibrosis patients
4. Hospital therapy improves exercise tolerance and lung function in cystic fibrosis
5. Frequent antibiotic therapy improves survival of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection
6. In vitro and in vivo activity of DL-8280, a new oxacine derivative
7. In vitro activity of Bayer 09867. A new quinolone derivative compared with those of other antimicrobial agents
8. Pharmacokinetics and pharmacodynamics of ciprofloxacin in cystic fibrosis patients
9. Oral ciprofloxacin therapy of infections due to Pseudomonas aeruginosa
10. Ciprofloxacin in cystic fibrosis
11. Oral ciprofloxacin compared with conventional intravenous treatment for Pseudomonas aeruginosa infection in adults with cystic fibrosis
12. Summary equations of reference values
13. Tables of critical values for the Pratt matched pair signed rank statistic
14. Antibiotic treatment of Staphylococcus aureus infection in cystic fibrosis
15. Antibiotic treatment of Haemophilus influenzae and Haemophilus parainfluenzae in patients with cystic fibrosis
16. Azlocillin compared with carbenicillin in the treatment of bronchopulmonary infection due to Pseudomonas aeruginosa in cystic fibrosis
17. Antimicrobial activity of ciprofloxacin against Pseudomonas aeruginosa, Escherichia coli and Staphylococcus aureus determined by the killing curve method: Antibiotic comparisons and synergistic interactions
18. Resistance to ciprofloxacin
19. Ciprofloxacin resistant Pseudomonas
20. Ciprofloxacin in the treatment of chronic bronchitis